These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 31118572)

  • 21. Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer.
    Shi SJ; Wang LJ; Han DH; Wu JH; Jiao D; Zhang KL; Chen JW; Li Y; Yang F; Zhang JL; Zheng GX; Yang AG; Zhao AZ; Qin WJ; Wen WH
    Theranostics; 2019; 9(5):1247-1263. PubMed ID: 30867828
    [No Abstract]   [Full Text] [Related]  

  • 22. Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy.
    Jiang W; Chen J; Gong C; Wang Y; Gao Y; Yuan Y
    J Nanobiotechnology; 2020 Mar; 18(1):50. PubMed ID: 32188463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy.
    Zheng C; Zheng M; Gong P; Deng J; Yi H; Zhang P; Zhang Y; Liu P; Ma Y; Cai L
    Biomaterials; 2013 Apr; 34(13):3431-8. PubMed ID: 23375952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA polymerase theta repression enhances the docetaxel responsiveness in metastatic castration-resistant prostate cancer.
    Kuei CH; Lin HY; Lin MH; Lee HH; Lin CH; Lee WJ; Chen YL; Lu LS; Zheng JQ; Hung RC; Chiu HW; Chen KC; Lin YF
    Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165954. PubMed ID: 32877750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).
    Hour TC; Chung SD; Kang WY; Lin YC; Chuang SJ; Huang AM; Wu WJ; Huang SP; Huang CY; Pu YS
    Arch Toxicol; 2015 Apr; 89(4):591-605. PubMed ID: 24888374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ABCB1-mediated docetaxel resistance reversed by erastin in prostate cancer.
    Chen F; Wu S; Kuang N; Zeng Y; Li M; Xu C
    FEBS J; 2024 Jul; 291(14):3249-3266. PubMed ID: 38712529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
    He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
    Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docetaxel-carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer.
    Hoang B; Ernsting MJ; Murakami M; Undzys E; Li SD
    Int J Pharm; 2014 Aug; 471(1-2):224-33. PubMed ID: 24853460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre- and Post-Transcriptional Regulation of cFLIP for Effective Cancer Therapy Using pH-Ultrasensitive Nanoparticles.
    Phung CD; Tran TH; Choi JY; Jeong JH; Ku SK; Yong CS; Kim JO
    ACS Appl Mater Interfaces; 2021 Feb; 13(5):5999-6010. PubMed ID: 33506682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preparation and Biocompatibility Evaluation of PEG-PLL/RGD-PEG-DSPE/Phospholipid/CaP Nanoparticles.
    Huang J; Zhang X; Wu Z; Wu Y; Wu X; Wang Y; Jiang H; Ma J; He Z
    J Biomed Nanotechnol; 2018 Jan; 14(1):98-113. PubMed ID: 29463368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Codelivery of BV6 and anti-IL6 siRNA by hyaluronate-conjugated PEG-chitosan-lactate nanoparticles inhibits tumor progression.
    Salimifard S; Karoon Kiani F; Sadat Eshaghi F; Izadi S; Shahdadnejad K; Masjedi A; Heydari M; Ahmadi A; Hojjat-Farsangi M; Hassannia H; Mohammadi H; Boroumand-Noughabi S; Keramati MR; Jadidi-Niaragh F
    Life Sci; 2020 Nov; 260():118423. PubMed ID: 32941896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quercetin-loaded nanomicelles to circumvent human castration-resistant prostate cancer in vitro and in vivo.
    Zhao J; Liu J; Wei T; Ma X; Cheng Q; Huo S; Zhang C; Zhang Y; Duan X; Liang XJ
    Nanoscale; 2016 Mar; 8(9):5126-38. PubMed ID: 26875690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective systemic siRNA delivery using dual-layer protected long-circulating nanohydrogel containing an inorganic core.
    Yin Y; Lee MS; Lee JE; Lim SY; Kim ES; Jeong J; Kim D; Kim J; Lee DS; Jeong JH
    Biomater Sci; 2019 Aug; 7(8):3297-3306. PubMed ID: 31187795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Turning an antiviral into an anticancer drug: nanoparticle delivery of acyclovir monophosphate.
    Yao J; Zhang Y; Ramishetti S; Wang Y; Huang L
    J Control Release; 2013 Sep; 170(3):414-20. PubMed ID: 23791977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors.
    Butt AM; Amin MC; Katas H; Abdul Murad NA; Jamal R; Kesharwani P
    Mol Pharm; 2016 Dec; 13(12):4179-4190. PubMed ID: 27934479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
    Park SE; Kim HG; Kim DE; Jung YJ; Kim Y; Jeong SY; Choi EK; Hwang JJ; Kim CS
    Invest New Drugs; 2018 Apr; 36(2):195-205. PubMed ID: 29110173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic Effect of Tangeretin and Atorvastatin for Colon Cancer Combination Therapy: Targeted Delivery of These Dual Drugs Using RGD Peptide Decorated Nanocarriers.
    Bao H; Zheng N; Li Z; Zhi Y
    Drug Des Devel Ther; 2020; 14():3057-3068. PubMed ID: 32801644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer (review).
    Magadoux L; Isambert N; Plenchette S; Jeannin JF; Laurens V
    Int J Oncol; 2014 Sep; 45(3):919-28. PubMed ID: 24969394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving radio-chemotherapy efficacy of prostate cancer by co-deliverying docetaxel and dbait with biodegradable nanoparticles.
    Liu N; Ji J; Qiu H; Shao Z; Wen X; Chen A; Yao S; Zhang X; Yao H; Zhang L
    Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):305-314. PubMed ID: 31858836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.